價格 | 詢價 | ||
包裝 | 20μl | 50μl | 100μl |
最小起訂量 | 1μl |
發(fā)貨地 | 湖北 |
更新日期 | 2025-05-09 |
中文名稱:MOB1B抗體 | 英文名稱:Rabbit Polyclonal MOB1B Antibody |
品牌: 艾普蒂 | 產(chǎn)地: 武漢 |
保存條件: Stored at -20°C for 157 year. Avoid repeated freeze / thaw cycles. | 產(chǎn)品類別: 抗體 |
重組: 否 | 應用: WB: IHC-P:?IHC-F:?ICC/IF: IP:FC:ChIP:?ELISA |
種屬反應性: Human,Mouse,Rat | 宿主: Rabbit |
偶聯(lián)物: 無 | 靶點: MOB1B |
WB | 咨詢技術 | Human,Mouse,Rat |
IF | 咨詢技術 | Human,Mouse,Rat |
IHC | 咨詢技術 | Human,Mouse,Rat |
ICC | 技術咨詢 | Human,Mouse,Rat |
FCM | 咨詢技術 | Human,Mouse,Rat |
Elisa | 1/1000-1/2000 | Human,Mouse,Rat |
以下是關于MOB1B抗體的3篇參考文獻及其簡要摘要:
1. **"MOB1 mediates the Hippo pathway regulation of cell proliferation and apoptosis"**
- **作者**: Hergovich, A. et al.
- **摘要**: 該研究通過MOB1B抗體驗證了MOB1B與LATS激酶的相互作用,證明其在Hippo信號通路中調控細胞增殖和凋亡的核心作用,并揭示其磷酸化狀態(tài)對通路活性的影響。
2. **"The role of MOB1B in tumor suppression and genomic stability"**
- **作者**: Xiong, J. et al.
- **摘要**: 利用MOB1B特異性抗體進行免疫沉淀實驗,發(fā)現(xiàn)MOB1B缺失導致Hippo通路失調,促進腫瘤發(fā)生,且與基因組不穩(wěn)定性及癌癥預后不良相關。
3. **"Phosphorylation-dependent regulation of MOB1B in mitotic progression"**
- **作者**: Dong, L. et al.
- **摘要**: 通過Western blot和免疫熒光(使用MOB1B抗體),研究發(fā)現(xiàn)MOB1B的磷酸化修飾對其在有絲分裂中的定位及調控染色體分離至關重要。
4. **"MOB1B/1A isoforms differentially regulate YAP/TAZ activity in cellular differentiation"**
- **作者**: Kanai, F. et al.
- **摘要**: 研究通過MOB1B抗體區(qū)分MOB1A和MOB1B亞型的功能差異,發(fā)現(xiàn)MOB1B特異性調控YAP/TAZ活性,影響細胞分化和組織發(fā)育。
(注:以上文獻標題及作者為示例性內容,實際引用時需以真實文獻為準。)
The MOB1B antibody is a crucial tool for studying the MOB1B protein, a member of the MOB (Mps One Binder) superfamily involved in regulating cell cycle progression, apoptosis, and the Hippo signaling pathway. MOB1B, along with its homolog MOB1A, acts as a conserved component of the Hippo pathway, which controls organ size and tumor suppression by inhibiting cell proliferation and promoting apoptosis. MOB1B interacts with MST1/2 kinases and LATS1/2 kinases, facilitating their phosphorylation and activation. This cascade ultimately leads to the inactivation of YAP/TAZ transcriptional co-activators, critical for cell growth and survival. Dysregulation of MOB1B is implicated in cancers, as altered Hippo signaling often correlates with tumorigenesis and metastasis.
MOB1B antibodies are widely used in Western blotting, immunofluorescence, and immunoprecipitation to detect endogenous MOB1B expression, localization, and protein interactions. They help elucidate MOB1B's role in maintaining genomic stability, mitotic exit, and its crosstalk with other pathways like Wnt or Notch. Researchers also employ these antibodies to investigate MOB1B's differential expression in cancer tissues versus normal tissues, its prognostic significance, and responses to targeted therapies. Specificity is critical, as MOB1B shares high sequence similarity with MOB1A, requiring rigorous validation via knockout/knockdown controls. Such antibodies are indispensable for understanding MOB1B's multifaceted roles in development, homeostasis, and disease.
成立日期 | 2024-06-24 (2年) | 注冊資本 | 50萬(元) |
員工人數(shù) | 1-10人 | 年營業(yè)額 | ¥ 100萬以內 |
主營行業(yè) | 中間體,化學試劑 | 經(jīng)營模式 | 貿易,工廠,試劑,定制,服務 |
產(chǎn)品名稱 | 價格 | 公司名稱 | 報價日期 | |
---|---|---|---|---|
¥960.00 |
VIP10年
|
北京索萊寶科技有限公司
|
2025-07-30 | |
¥1950 |
VIP3年
|
上海滬震實業(yè)有限公司
|
2025-08-01 | |
詢價 |
VIP3年
|
維百奧(北京)生物科技有限公司
|
2025-08-01 | |
¥1280 |
湖北艾普蒂生物工程有限公司
|
2025-06-04 |